Harrow (HROW) Stock Still Looks Undervalued As Its 229% Three Year Run Continues
Harrow to Participate in Two Investor Conferences in November
Harrow Inc (HROW) Q3 2026 Earnings Call Highlights: Record Revenue of $99. ...
BTIG Reiterates Buy on Harrow, Maintains $63 Price Target
Harrow (HROW) Q3 2026 Earnings Call Transcript
Harrow Q3 Earnings Call Highlights
Harrow, Inc. (HROW) Q3 2026 Earnings Call Transcript
Harrow Health, Inc. Q3 2026 Earnings Call Summary
Harrow Q3 2026 Earnings Call Transcript
Harrow (HROW) Reports Q3 Earnings: What Key Metrics Have to Say
Harrow: Q3 Earnings Snapshot
Harrow Announces Third Quarter 2026 Financial Results
Harrow Affirms FY2026 Sales Guidance of $350.000M-$365.000M vs $349.747M Est
Harrow Q3 EPS $0.25 Beats $0.22 Estimate, Sales $99.297M Beat $98.501M Estimate
Harrow (HROW) Launches HarrowRx, Is The Stock Still Undervalued?
Learn Why The Bull Case For Harrow (HROW) Could Change Following Pharmacy Platform Launch
PHIL Partners with Harrow to Power HarrowRx, One Prescribing Destination for Harrow’s Eye Care Portfolio
Harrow Launches HarrowRx Platform
Harrow's Top Two Drugs Alone Can Justify Its Current Valuation
Harrow To Report Third Quarter 2026 Financial Results After Market Close on November 9, 2026
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.